RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field
Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.
You may also be interested in...
Phio Pharma Takes RXi’s Self-Delivering RNAi Technology, Refocuses On Immuno-Oncology
RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.
Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
Geert Cauwenbergh joins RXi as CEO
RNAi focused biotech, RXi Pharmaceuticals, has appointed Dr Geert Cauwenbergh president and CEO and a member of the board of directors. Dr Cauwenbergh was most recently chair and CEO of Barrier Therapeutics.